News
XCUR
1.080
+1.89%
0.020
Exicure Inks $4.8M Asset Deal to Strengthen Balance Sheet
Benzinga · 3d ago
Exicure Agrees to Sell GPC-100 Program Assets
TipRanks · 4d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 4d ago
Exicure agrees to sell GPC-100 assets for $4.8M; shares rally over 21%
Seeking Alpha · 4d ago
Exicure agrees to sell GPC-100 program assets for $4.8M
TipRanks · 4d ago
Exicure Agrees To Sell Its GPC-100 Program Assets To GPCRT For ~$4.8M In Cash
Benzinga · 4d ago
Weekly Report: what happened at XCUR last week (1102-1106)?
Weekly Report · 5d ago
Weekly Report: what happened at XCUR last week (1026-1030)?
Weekly Report · 11/02 09:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 10/29 21:15
Weekly Report: what happened at XCUR last week (1019-1023)?
Weekly Report · 10/26 09:00
Weekly Report: what happened at XCUR last week (1012-1016)?
Weekly Report · 10/19 09:00
Weekly Report: what happened at XCUR last week (1005-1009)?
Weekly Report · 10/12 09:00
Weekly Report: what happened at XCUR last week (0928-1002)?
Weekly Report · 10/05 09:00
Weekly Report: what happened at XCUR last week (0921-0925)?
Weekly Report · 09/28 09:00
Weekly Report: what happened at XCUR last week (0914-0918)?
Weekly Report · 09/21 09:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 09/17 21:06
Exicure Receives Nasdaq Extension Amid Ongoing Listing Risk
TipRanks · 09/16 15:34
Exicure gets Nasdaq compliance extension
Seeking Alpha · 09/16 12:49
Exicure Receives Nasdaq Extension Through December 2 To Regain Compliance
Benzinga · 09/16 12:01
Weekly Report: what happened at XCUR last week (0907-0911)?
Weekly Report · 09/14 09:00
More
Webull provides a variety of real-time XCUR stock news. You can receive the latest news about Exicure Inc through multiple platforms. This information may help you make smarter investment decisions.
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.